<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001204</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUMCH-NMRM26</org_study_id>
    <nct_id>NCT05001204</nct_id>
  </id_info>
  <brief_title>68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor</brief_title>
  <official_title>68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label positron emission tomography/computed tomography (PET/CT) study to&#xD;
      investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in&#xD;
      Gastrointestinal stromal tumor（GIST）patients. A single dose of 55.5 to 148 MBq(1.5-4 mCi) of&#xD;
      68Ga-NOTA-RM26 will be injected intravenously. Patients underwent whole-body PET/CT scans at&#xD;
      30-90 minutes after intravenous injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rm26 is a bioactive polypeptide containing 9 amino acid residues, which can specifically bind&#xD;
      to gastrin releasing peptide receptor (GRPR, BB2 receptor). Previous studies have confirmed&#xD;
      that there are a large number of GRPR receptors in human common types of tumors, such as lung&#xD;
      cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, glioma and&#xD;
      gastrointestinal tumors. Therefore, the use of various radionuclide labeled gastrin releasing&#xD;
      peptide receptor analogues RM26 for tumor targeted imaging and treatment greatly improves the&#xD;
      early detection rate of tumor, and has important clinical significance and value in tumor&#xD;
      staging, prognosis evaluation and curative effect evaluation.This prospective pilot study&#xD;
      investigated the use of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide&#xD;
      receptor (GRPR), for evaluating breast cancer using positron-emission tomography/computed&#xD;
      tomography (PET/CT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor</measure>
    <time_frame>1 year</time_frame>
    <description>The quantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (suv) of the tracer in Gastrointestinal stromal tumors will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse events within 1 week after the injection and scanning of patients and patients will be followed and assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA-RM26 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-NOTA-RM26</intervention_name>
    <description>68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans</description>
    <arm_group_label>68Ga-NOTA-RM26 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in suspicion of gastrointestinal stromal tumors by CT or ultrasonography,and&#xD;
             being able to provide basic information and sign the written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or&#xD;
             liver failure, inability to fulfill the study, and undergoing any preceding local or&#xD;
             systemic therapies that might interfere with GRPR binding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rongxi Wang</last_name>
    <phone>+8619800370331</phone>
    <email>pumch_jacobwong@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaohui Zhu, MD</last_name>
    <phone>13611093752</phone>
    <email>13611093752@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongxi Wang</last_name>
      <phone>+8619800370331</phone>
      <email>pumch_jacobwong@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>RM26</keyword>
  <keyword>GRPR</keyword>
  <keyword>gastrin-releasing peptide receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>68Ga-NOTA-RM26</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

